

FWO DMP Template - Flemish Standard Data Management Plan

Version KU Leuven

Project supervisors (from application round 2018 onwards) and fellows (from application round 2020 onwards) will, upon being awarded their project or fellowship, be invited to develop their answers to the data management related questions into a DMP. The FWO expects a **completed DMP no later than 6 months after the official start date** of the project or fellowship. The DMP should not be submitted to FWO but to the research co-ordination office of the host institute; FWO may request the DMP in a random check.

At the end of the project, the **final version of the DMP** has to be added to the final report of the project; this should be submitted to FWO by the supervisor-spokesperson through FWO's e-portal. This DMP may of course have been updated since its first version. The DMP is an element in the final evaluation of the project by the relevant expert panel. Both the DMP submitted within the first 6 months after the start date and the final DMP may use this template.

The DMP template used by the Research Foundation Flanders (FWO) corresponds with the Flemish Standard Data Management Plan. This Flemish Standard DMP was developed by the Flemish Research Data Network (FRDN) Task Force DMP which comprises representatives of all Flemish funders and research institutions. This is a standardized DMP template based on the previous FWO template that contains the core requirements for data management planning. To increase understanding and facilitate completion of the DMP, a standardized **glossary** of definitions and abbreviations is available via the following [link](#).

1. General Project Information	
Name Grant Holder & ORCID	Maurilio Sampaolesi, https://orcid.org/0000-0002-2422-3757
Contributor name(s) (+ ORCID) & roles	
Project number ¹ & title	3M240030 Circulating extracellular vesicle cargo perturbations in skeletal muscle chronic regeneration and aging
Funder(s) GrantID ²	FWO G058924N
Affiliation(s)	<input checked="" type="checkbox"/> KU Leuven <input type="checkbox"/> Universiteit Antwerpen <input type="checkbox"/> Universiteit Gent <input type="checkbox"/> Universiteit Hasselt <input type="checkbox"/> Vrije Universiteit Brussel <input type="checkbox"/> Other: ROR identifier KU Leuven: 05f950310
Please provide a short project description	<p>In thirty years, the global population of seniors (60 years old) is estimated to more than double its size. This trend will affect the number of patients affected by sarcopenia, a syndrome characterized by loss of muscle mass and strength without body mass reduction. Various factors contribute to sarcopenia, including diet, chronic illness, physical activity and physiological ageing, leading to poor quality of life. The main underlying cause is an imbalance in protein synthesis and degradation that leads to muscle atrophy. We have already demonstrated how ageing negatively impacts the regenerative potential of human mesoangioblasts, muscle stem cells that contribute to repairing muscle fibres in adulthood. In addition, we and other groups proved that small non-coding RNAs (miRNAs) are able to modulate muscle mass and function and can be delivered as extracellular vesicle cargoes. Our working hypothesis is that ageing muscles have a different miRNA signature compared to young muscles and that by modulating this signature we can recover old muscle features. Therefore, we will apply miRNAs-based therapy to murine models of sarcopenia, assessing functional regeneration in skeletal muscles. We will therefore investigate inter and intrapopulation heterogeneity during muscle ageing via single-cell RNA sequencing. Finally, we will test conserved miRNAs on old human muscle stem cells to revert the hallmarks of ageing.</p>

¹ “Project number” refers to the institutional project number. This question is optional. Applicants can only provide one project number.

² Funder(s) GrantID refers to the number of the DMP at the funder(s), here one can specify multiple GrantIDs if multiple funding sources were used.

2. Research Data Summary

List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data ³.

Dataset Name	Description	New or Reused	Digital or Physical	ONLY FOR DIGITAL DATA	ONLY FOR DIGITAL DATA	ONLY FOR DIGITAL DATA	ONLY FOR PHYSICAL DATA
				Digital Data Type	Digital Data Format	Digital Data Volume (MB, GB, TB)	Physical Volume
Objective 1: Depicting the effects of miRNA signature in muscle function: circulating exosome of young and aged mice	characterization of exosomes in pathological models of skeletal muscle disease	<input checked="" type="checkbox"/> Generate new data <input checked="" type="checkbox"/> Reuse existing data	<input checked="" type="checkbox"/> Digital <input checked="" type="checkbox"/> Physical	<input type="checkbox"/> Audiovisual <input checked="" type="checkbox"/> Images <input type="checkbox"/> Sound <input checked="" type="checkbox"/> Numerical <input checked="" type="checkbox"/> Textual <input type="checkbox"/> Model <input type="checkbox"/> Software <input type="checkbox"/> Other:	<input checked="" type="checkbox"/> .csv <input checked="" type="checkbox"/> .pdf <input checked="" type="checkbox"/> .txt	<input type="checkbox"/> < 1 GB <input checked="" type="checkbox"/> < 100 GB <input type="checkbox"/> < 1 TB <input type="checkbox"/> < 5 TB <input type="checkbox"/> > 5 TB <input type="checkbox"/> NA	Physical data will be stored at -20°C (CRISPR/Cas9 related plasmids and constructs; DNA), at -80°C (RNA) and at -150°C (iETV2- hiPSCs; DMD-iETV2- hiPSCs).
Objective 2: In vivo miRNA perturbation studies to counteract sarcopenic mice	extensive analysis on newly identified miRNAs in regulating cellular/gene pathways	<input checked="" type="checkbox"/> Generate new data <input checked="" type="checkbox"/> Reuse existing data	<input checked="" type="checkbox"/> Digital <input checked="" type="checkbox"/> Physical	<input type="checkbox"/> Audiovisual <input checked="" type="checkbox"/> Images <input type="checkbox"/> Sound <input checked="" type="checkbox"/> Numerical <input checked="" type="checkbox"/> Textual <input type="checkbox"/> Model <input type="checkbox"/> Software <input type="checkbox"/> Other:	<input checked="" type="checkbox"/> .csv <input checked="" type="checkbox"/> .pdf <input checked="" type="checkbox"/> .txt	<input type="checkbox"/> < 1 GB <input checked="" type="checkbox"/> < 100 GB <input type="checkbox"/> < 1 TB <input type="checkbox"/> < 5 TB <input type="checkbox"/> > 5 TB <input type="checkbox"/> NA	Physical data will be stored at -20°C (CRISPR/Cas9 related plasmids and constructs; DNA), at -80°C (RNA) and at -150°C (iETV2- hiPSCs; DMD-iETV2- hiPSCs).
Objective 3: Single cell RNA	10X single cell RNAseq analysis o	<input checked="" type="checkbox"/> Generate new	<input checked="" type="checkbox"/> Digital	<input type="checkbox"/> Audiovisual	<input checked="" type="checkbox"/> .csv	<input type="checkbox"/> < 1 GB	Physical data will be stored at -20°C

³ Add rows for each dataset you want to describe.

seq analysis in animal model for sarcopenia in control and regenerating conditions	understand the effect of the PMC on the heterogeneity of stem cell populations during aging	data <input checked="" type="checkbox"/> Reuse existing data	<input checked="" type="checkbox"/> Physical	<input checked="" type="checkbox"/> Images <input type="checkbox"/> Sound <input checked="" type="checkbox"/> Numerical <input checked="" type="checkbox"/> Textual <input type="checkbox"/> Model <input type="checkbox"/> Software <input type="checkbox"/> Other:	<input checked="" type="checkbox"/> .pdf <input checked="" type="checkbox"/> .txt	<input checked="" type="checkbox"/> < 100 GB <input type="checkbox"/> < 1 TB <input type="checkbox"/> < 5 TB <input type="checkbox"/> > 5 TB <input type="checkbox"/> NA	(CRISPR/Cas9 related plasmids and constructs; DNA), at -80°C (RNA) and at -150°C (iETV2- hiPSCs; DMD-iETV2- hiPSCs).
Objective 4: Inducing hypertrophy by administration of miRNA in human myogenic progenitors	Empty and miRs exosomes will be administered In 2D and 3D human skeletal muscle models	<input checked="" type="checkbox"/> Generate new data <input checked="" type="checkbox"/> Reuse existing data	<input checked="" type="checkbox"/> Digital <input checked="" type="checkbox"/> Physical	<input type="checkbox"/> Audiovisual <input checked="" type="checkbox"/> Images <input type="checkbox"/> Sound <input checked="" type="checkbox"/> Numerical <input checked="" type="checkbox"/> Textual <input type="checkbox"/> Model <input type="checkbox"/> Software <input type="checkbox"/> Other:	<input checked="" type="checkbox"/> .csv <input checked="" type="checkbox"/> .pdf <input checked="" type="checkbox"/> .txt	<input type="checkbox"/> < 1 GB <input checked="" type="checkbox"/> < 100 GB <input type="checkbox"/> < 1 TB <input type="checkbox"/> < 5 TB <input type="checkbox"/> > 5 TB <input type="checkbox"/> NA	Physical data will be stored at -20°C (CRISPR/Cas9 related plasmids and constructs; DNA), at -80°C (RNA) and at -150°C (iETV2- hiPSCs; DMD-iETV2- hiPSCs).

GUIDANCE:

The data description forms the basis of your entire DMP, so make sure it is detailed and complete. It includes digital and physical data and encompasses the whole spectrum ranging from raw data to processed and analysed data including analysis scripts and code. Physical data are all materials that need proper management because they are valuable, difficult to replace and/or ethical issues are associated. Materials that are not considered data in an RDM context include your own manuscripts, theses and presentations; documentation is an integral part of your datasets and should be described under documentation/metadata.

[RDM Guidance on data](#)

If you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per dataset or data type.

Some iPSC lines described in have been previously generated and reported in the following papers:
doi: 10.1016/j.stemcr.2021.12.019
doi: 10.1038/s41398-019-0535-1
Preliminary studies on extracellular vesicles are already reported in the following papers:
doi: 10.3389/fphys.2023.1130063
doi: 10.3389/fimmu.2022.977617
doi: 10.3390/ijms24054944

Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.	<input checked="" type="checkbox"/> Yes, human subject data; provide SMEC or EC approval number: S65190 and S66794 <input checked="" type="checkbox"/> Yes, animal data; provide ECD reference number: 052/2022 <input type="checkbox"/> Yes, dual use; provide approval number: <input type="checkbox"/> No Additional information:
Will you process personal data ⁴ ? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).	<input checked="" type="checkbox"/> Yes (provide PRET G-number or EC S-number below) S65190 (G-2021-3128) and S66794 (G-2022-5381) <input type="checkbox"/> No Additional information:
Does your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, ...)? If so, please comment per dataset or data type where appropriate.	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If yes, please comment:
Do existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material/Data transfer agreements, research collaboration agreements)? If so, please explain to what data they relate and what restrictions are in place.	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If yes, please explain:
Are there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you (re)use? If so, please explain to what data they relate and which restrictions will be asserted.	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If yes, please explain:

⁴ See Glossary Flemish Standard Data Management Plan

3. Documentation and Metadata

Clearly describe what approach will be followed to capture the accompanying information necessary to keep **data understandable and usable**, for yourself and others, now and in the future (e.g. in terms of documentation levels and types required, procedures used, Electronic Lab Notebooks, README.txt files, Codebook.tsv etc. where this information is recorded).

[*RDM guidance on documentation and metadata.*](#)

Documentation and metadata linked to each experiment will be documented by research groups in hard copy lab notebooks for this project. This includes the research design, protocol, context of data collection, data collection methods, quality control procedures, processing and analysis procedures.

Digital data:

- Experimental design and protocol (.docx file)
- Steps involved in data analysis and relevant analysis scripts (R, ImageJ)
- Raw data (specific file format according to data type)
- Analysed data (specific file format according to data type)

Physical data:

Samples used for the experiments will be documented and stored for up to three years after the end of the project. Storage will be in fixative or in freezers depending on the kind of sample. Immunohistological stained slides will be stored in appropriate boxes in a dry place or freezer.

Will a metadata standard be used to make it easier to **find and reuse the data**?

If so, please specify which metadata standard will be used. If not, please specify which metadata will be created to make the data easier to find and reuse.

REPOSITORIES COULD ASK TO DELIVER METADATA IN A CERTAIN FORMAT, WITH SPECIFIED ONTOLOGIES AND VOCABULARIES, I.E. STANDARD LISTS WITH UNIQUE IDENTIFIERS.

☐ Yes

☒ No

If yes, please specify (where appropriate per dataset or data type) which metadata standard will be used:

If no, please specify (where appropriate per dataset or data type) which metadata will be created:

We will adopt a single, well-defined file-folder structure and file-naming rules. Every data folder will be accompanied by appropriate metadata files consisting of a readme.txt with info on nomenclature, file format, software and adopted data standards.

4. Data Storage & Back-up during the Research Project

<p>Where will the data be stored?</p> <p><i>Consult the interactive KU Leuven storage guide to find the most suitable storage solution for your data.</i></p>	<p><input checked="" type="checkbox"/> Shared network drive (J-drive)</p> <p><input type="checkbox"/> Personal network drive (I-drive)</p> <p><input checked="" type="checkbox"/> OneDrive (KU Leuven)</p> <p><input type="checkbox"/> Sharepoint online</p> <p><input type="checkbox"/> Sharepoint on-premis</p> <p><input type="checkbox"/> Large Volume Storage</p> <p><input type="checkbox"/> Digital Vault</p> <p><input type="checkbox"/> Other:</p>
<p>How will the data be backed up?</p> <p><i>WHAT STORAGE AND BACKUP PROCEDURES WILL BE IN PLACE TO PREVENT DATA LOSS?</i></p>	<p><input checked="" type="checkbox"/> Standard back-up provided by KU Leuven ICTS for my storage solution</p> <p><input type="checkbox"/> Personal back-ups I make (specify)</p> <p><input type="checkbox"/> Other (specify)</p>
<p>Is there currently sufficient storage & backup capacity during the project? If yes, specify concisely. If no or insufficient storage or backup capacities are available, then explain how this will be taken care of.</p>	<p><input checked="" type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>storage capacity of 2 TB with regular backup system</p> <p>If no, please specify:</p>
<p>How will you ensure that the data are securely stored and not accessed or modified by unauthorized persons?</p> <p><i>CLEARLY DESCRIBE THE MEASURES (IN TERMS OF PHYSICAL SECURITY, NETWORK SECURITY, AND SECURITY OF COMPUTER SYSTEMS AND FILES) THAT WILL BE TAKEN TO ENSURE THAT STORED AND TRANSFERRED DATA ARE SAFE.</i></p> <p>Guidance on security for research data</p>	<p>The host institute provides a secure data storage system (KU Leuven LUNA servers) with automated onsite back-up and mirroring. Every person has storage capacity of 2 TB with regular backup system (OneDrive) so the data will be stored there for active use and copies can be made and kept on personal devices. For active use of the data during the project, OneDrive will ensure data transfer between computers, and will also be stored on the KU Leuven LUNA Large Volume Storage space. Biological samples will be taken, and stored in labelled fridges, freezers and closets in the lab. The inventory of all locations is shared on the KU Leuven LUNA Shared drive.</p> <p>All storage spaces (OneDrive and J drive) are hosted in the KU Leuven ICTS data centre, with a mirror in the second ICTS center. They are accessible only with my KU Leuven credentials, that provides disaster recovery and additional back-up capacity with guaranteeing long-term data availability.</p>

What are the expected costs for data storage and backup during the research project? How will these costs be covered?	Back-up cost per Tb (KU Leuven ICTS): 295€/year Expected amount of data (5 Tb). Digital vault for private data: windows server (KU Leuven ICTS): 1302 €/year The costs will be covered by part of the allocated project budget.
---	--

5. Data Preservation after the end of the Research Project	
<p>Which data will be retained for at least five years (or longer, in agreement with other retention policies that are applicable) after the end of the project? In case some data cannot be preserved, clearly state the reasons for this (e.g. legal or contractual restrictions, storage/budget issues, institutional policies...).</p> <p>Guidance on data preservation</p>	<p><input checked="" type="checkbox"/> All data will be preserved for 10 years according to KU Leuven RDM policy</p> <p><input type="checkbox"/> All data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for human use and for clinical experiments on humans</p> <p><input type="checkbox"/> Certain data cannot be kept for 10 years (explain)</p>
<p>Where will these data be archived (stored and curated for the long-term)?</p> <p><i>Dedicated data repositories are often the best place to preserve your data. Data not suitable for preservation in a repository can be stored using a KU Leuven storage solution, consult the interactive KU Leuven storage guide.</i></p>	<p><input checked="" type="checkbox"/> KU Leuven RDR</p> <p><input type="checkbox"/> Large Volume Storage (longterm for large volumes)</p> <p><input checked="" type="checkbox"/> Shared network drive (J-drive)</p> <p><input type="checkbox"/> Other (specify):</p>
<p>What are the expected costs for data preservation during the expected retention period? How will these costs be covered?</p>	<p>1200 EUR/year</p> <p>The costs will be covered by part of the allocated project budget.</p>

6. Data Sharing and Reuse

<p>Will the data (or part of the data) be made available for reuse after/during the project? Please explain per dataset or data type which data will be made available.</p> <p><i>NOTE THAT 'AVAILABLE' DOES NOT NECESSARILY MEAN THAT THE DATA SET BECOMES OPENLY AVAILABLE, CONDITIONS FOR ACCESS AND USE MAY APPLY. AVAILABILITY IN THIS QUESTION THUS ENTAILS BOTH OPEN & RESTRICTED ACCESS. FOR MORE INFORMATION: HTTPS://WIKI.SURFNET.NL/DISPLAY/STANDARDS/INFO-EU-REPO/#INFOEUREPO-ACCESSRIGHTS</i></p>	<p> <input checked="" type="checkbox"/> Yes, as open data <input type="checkbox"/> Yes, as embargoed data (temporary restriction) <input type="checkbox"/> Yes, as restricted data (upon approval, or institutional access only) <input type="checkbox"/> No (closed access) <input checked="" type="checkbox"/> Other, please specify: </p> <p>Sequencing data will be submitted to public databases (EBI-ENA/NCBI-SRA), where they will be permanently archived to preserve access to the public.</p> <p>Written progress reports, thesis will be stored for internal purposes and can be accessed by KU Leuven researcher upon request.</p> <p>For most publications we expect that we will make the data publicly available on data repositories.</p>
<p>If access is restricted, please specify who will be able to access the data and under what conditions.</p>	<p>In an Open Access repository</p>
<p>Are there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)? Please explain per dataset or data type where appropriate.</p>	<p> <input type="checkbox"/> Yes, privacy aspects <input type="checkbox"/> Yes, intellectual property rights <input type="checkbox"/> Yes, ethical aspects <input type="checkbox"/> Yes, aspects of dual use <input type="checkbox"/> Yes, other <input checked="" type="checkbox"/> No </p> <p>If yes, please specify:</p>

<p>Where will the data be made available? If already known, please provide a repository per dataset or data type.</p>	<p><input checked="" type="checkbox"/> KU Leuven RDR <input type="checkbox"/> Other data repository (specify) <input type="checkbox"/> Other (specify) or in an Open access repository</p>
<p>When will the data be made available?</p>	<p><input checked="" type="checkbox"/> Upon publication of research results <input type="checkbox"/> Specific date (specify) <input type="checkbox"/> Other (specify)</p>
<p>Which data usage licenses are you going to provide? If none, please explain why.</p> <p><i>A DATA USAGE LICENSE INDICATES WHETHER THE DATA CAN BE REUSED OR NOT AND UNDER WHAT CONDITIONS. IF NO LICENCE IS GRANTED, THE DATA ARE IN A GREY ZONE AND CANNOT BE LEGALLY REUSED. DO NOTE THAT YOU MAY ONLY RELEASE DATA UNDER A LICENCE CHOSEN BY YOURSELF IF IT DOES NOT ALREADY FALL UNDER ANOTHER LICENCE THAT MIGHT PROHIBIT THAT.</i> Check the RDR guidance on licences for data and software sources code or consult the License selector tool to help you choose.</p>	<p><input checked="" type="checkbox"/> CC-BY 4.0 (data) <input type="checkbox"/> Data Transfer Agreement (restricted data) <input type="checkbox"/> MIT licence (code) <input type="checkbox"/> GNU GPL-3.0 (code) <input type="checkbox"/> Other (specify):</p> <p>All the studies will result in papers subjected to a peer review process. All accepted articles will be published under a CC-BY 4.0 license and also those articles that meet the open access requirements of funding agencies and would be submitted to PubMed as we did recently in Frontiers Cell and developmental Biology (doi: 10.3389/fcell.2022.878311) and all articles are published with open access under the Creative Commons CC-BY license (the current version is CC-BY, version 4.0).</p>
<p>Do you intend to add a PID/DOI/accession number to your dataset(s)? If already available, please provide it here.</p> <p><i>INDICATE WHETHER YOU INTEND TO ADD A PERSISTENT AND UNIQUE IDENTIFIER IN ORDER TO IDENTIFY AND RETRIEVE THE DATA.</i></p>	<p><input checked="" type="checkbox"/> Yes, a PID will be added upon deposit in a data repository <input type="checkbox"/> My dataset already has a PID <input type="checkbox"/> No</p>
<p>What are the expected costs for data sharing? How will these costs be covered?</p>	<p>The expected cost for data sharing will be low, since the use of OneDrive is free for KU Leuven members up to 1TB.</p>

7. Responsibilities

Who will manage data documentation and metadata during the research project?	Responsibility for generating data and ensuring data preservation and sharing is with the PI Maurilio Sampaolesi and lab manager Vicky Raets
Who will manage data storage and backup during the research project?	the PI Maurilio Sampaolesi, the PhD student Ashley Wang and lab manager Vicky Raets
Who will manage data preservation and sharing?	the PI Maurilio Sampaolesi, the PhD student Ashley Wang and lab manager Vicky Raets
Who will update and implement this DMP?	the PI Maurilio Sampaolesi and lab manager Vicky Raets